MedTrace Logo

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

NCT01888796 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-04-12

No results posted yet for this study

Summary

Examination of the effect of Linagliptin versus placebo on diastolic function in patients with type 2 diabetes mellitus and diastolic dysfunction as assessed by transthoracic echocardiography.

Furthermore the effect on serum levels of NT-pro BNP as a biomarker of heart failure will be investigated.

Conditions

  • Diabetes Mellitus Type 2 (T2DM)
  • Left Ventricular Diastolic Dysfunction

Interventions

DRUG

Linagliptin

DRUG

placebo

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Nikolaus Marx, Univ.-Prof. · Department of Internal Medicine I, RWTH Aachen University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888796 on ClinicalTrials.gov